Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GENB

Generate Biomedicines Inc

13.40

Jul 27 • 4:00 AM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM APGE NUVL BMRN INCY KRYS VKTX AXSM NBIX

| Held by: ARKG VTI IWM VXF VTWO IWO SBIO SCHA IWN ONEQ

Scroll to Statements

Index	RUT
Market Cap	1.72B
Enterprise Value	1.27B
Income	-
Sales	-
Book/sh	4.02
Cash/sh	4.03
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	312
IPO	Feb 27, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	3.34
P/C	3.32
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.17
Current Ratio	9.17
Debt/Eq	0.13
LT Debt/Eq	0.10
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-2.15
EPS next Q	-0.51
EPS this Y	50.83%
EPS next Y	4.03%
EPS next 5Y	27.56%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	May 07 BMO
EPS/Sales Surpr.	-110.63% 36.83%

Insider Own	57.06%
Insider Trans	14.74%
Inst Own	19.45%
Inst Trans	40.05%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-10.38%
SMA50	-6.38%
SMA200	-0.75%
Trades

Shs Outstand	128.19M
Shs Float	55.05M
Short Float	12.69%
Short Ratio	8.89
Short Interest	6.99M
52W High	18.18 -26.29%
52W Low	11.00 21.82%
Volatility	5.33% 6.46%
ATR (14)	0.87
RSI (14)	40.21
Beta	-
Rel Volume	0.00
Avg Volume	785.45K
Volume	63

Perf Week	-1.33%
Perf Month	-18.39%
Perf Quarter	4.69%
Perf Half Y	-
Perf YTD	-10.67%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	25.40
Prev Close	13.40
Price	13.40
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	H.C. Wainwright	Buy	$16
Mar-24-26	Initiated	Piper Sandler	Overweight	$24
Mar-24-26	Initiated	Morgan Stanley	Overweight	$20
Mar-24-26	Initiated	Guggenheim	Buy	$30
Mar-24-26	Initiated	Goldman	Buy	$26
Mar-24-26	Initiated	Cantor Fitzgerald	Overweight

Jul-10-26 08:57AM	Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -8.87%
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
Jun-22-26 08:00AM	AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts (PR Newswire) +9.66%
May-28-26 04:20PM	Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
May-07-26 06:24AM	Generate Biomedicines: Q1 Earnings Snapshot (Associated Press) -11.21%
06:16AM	Loading…
06:16AM	Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Co-founder & Independent Chair of the BoardDr. Noubar B. Afeyan Ph.D.

CEO & DirectorMr. Michael T. Nally M.B.A.

M.D.Dr. Jason E. Silvers J.D.

Co-Founder & CTODr. Gevorg Grigoryan Ph.D.

Co-FounderMs. Molly Gibson Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nally Michael	Chief Executive Officer	Mar 04 '26	Buy	12.00	20,000	240,000	572,707	Mar 06 04:55 PM
Grous Beth	Chief People Officer	Mar 02 '26	Buy	16.00	300	4,800	300	Mar 02 06:05 PM
Silvers Jason	President & CFO	Mar 02 '26	Buy	16.00	2,000	32,000	1,000	Mar 02 05:54 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:52 PM
Mendillo Jane L	Director	Mar 02 '26	Buy	16.00	1,500	24,000	1,500	Mar 02 05:47 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GENB

Generate Biomedicines Inc

Upgrade your Finviz experience